Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the different sensitivity to antineoplastic drugs and makes the treatment of ovarian tumours a challenge. For early-stage disease, as well as for heavily pre-treated patients with recurrent ovarian cancer, the benefit of chemotherapy remains uncertain. Clear-cell, mucinous, low-grade serous, and endometrioid carcinomas show different molecular characteristics, which require different therapeutic approaches. In the era of personalised cancer medicine, understanding the pathogenesis and the genetic background of each subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing the side effects. Furthermore, personal factors, such as the patient's performance status, should be taken into account in the management of ovarian cancer, with the aim of safeguarding the patients' quality of life.

Cont, N., Ferrero, A., Peccatori, F., D'Alonzo, M., Codacci-Pisanelli, G., Colombo, N., et al. (2015). Medical treatment of early stage and rare histological variants of epithelial ovarian cancer. ECANCERMEDICALSCIENCE, 9 [10.3332/ecancer.2015.584].

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer

Colombo, N;
2015

Abstract

Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the different sensitivity to antineoplastic drugs and makes the treatment of ovarian tumours a challenge. For early-stage disease, as well as for heavily pre-treated patients with recurrent ovarian cancer, the benefit of chemotherapy remains uncertain. Clear-cell, mucinous, low-grade serous, and endometrioid carcinomas show different molecular characteristics, which require different therapeutic approaches. In the era of personalised cancer medicine, understanding the pathogenesis and the genetic background of each subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing the side effects. Furthermore, personal factors, such as the patient's performance status, should be taken into account in the management of ovarian cancer, with the aim of safeguarding the patients' quality of life.
Articolo in rivista - Articolo scientifico
biological markers; ovarian neoplasm; personalised medicine
English
Cont, N., Ferrero, A., Peccatori, F., D'Alonzo, M., Codacci-Pisanelli, G., Colombo, N., et al. (2015). Medical treatment of early stage and rare histological variants of epithelial ovarian cancer. ECANCERMEDICALSCIENCE, 9 [10.3332/ecancer.2015.584].
Cont, N; Ferrero, A; Peccatori, F; D'Alonzo, M; Codacci-Pisanelli, G; Colombo, N; Biglia, N
File in questo prodotto:
File Dimensione Formato  
10281-99989.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 433.1 kB
Formato Adobe PDF
433.1 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/99989
Citazioni
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 10
Social impact